- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 25/36 - Opioid-abuse
Patent holdings for IPC class A61P 25/36
Total number of patents in this class: 699
10-year publication summary
24
|
30
|
23
|
51
|
70
|
72
|
71
|
55
|
80
|
17
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Banyu Pharmaceutical Co., Ltd. | 107 |
15 |
Taisho Pharmaceutical Co., Ltd. | 844 |
13 |
Indivior UK Limited | 201 |
12 |
Guangxi Jiufu Biotechnology Co., Ltd | 13 |
11 |
Intra-Cellular Therapies, Inc. | 378 |
10 |
University of Florida Research Foundation, Inc. | 3883 |
8 |
Altria Client Services LLC | 1866 |
7 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
7 |
Novartis AG | 11238 |
6 |
Hoffmann-La Roche Inc. | 3060 |
6 |
The Regents of the University of California | 18943 |
6 |
Takeda Pharmaceutical Company Limited | 2961 |
6 |
BioDelivery Sciences International, Inc. | 28 |
6 |
Demerx, Inc. | 73 |
6 |
Rhodes Technologies | 64 |
6 |
University of Kentucky Research Foundation | 643 |
6 |
Virginia Commonwealth University | 599 |
6 |
Indivior, Inc. | 17 |
6 |
Sen-jam Pharmaceutical LLC | 17 |
6 |
Hikma Pharmaceuticals USA Inc. | 131 |
6 |
Other owners | 544 |